Core Insights - enGene Holdings Inc. reported additional preliminary data from the pivotal cohort of its ongoing Phase 2 LEGEND trial for detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients [1] Group 1: Company Overview - enGene Holdings Inc. is a clinical-stage, non-viral genetic medicines company [1] Group 2: Clinical Trial Information - The LEGEND trial is focused on patients with carcinoma in situ (CIS) with or without concomitant conditions [1]